Supplemental Online Content

Pliakos EE, Ziakas PD, Mylonakis E. Economic analysis of infectious disease consultation for *Staphylococcus aureus* bacteremia among hospitalized patients. *JAMA Netw Open*. 2022;5(9):e2234186. doi:10.1001/jamanetworkopen.2022.34186

eTable. Characteristics of Studies Used to Obtain Base-Case Effectiveness Estimates

eFigure. Incremental Cost-effectiveness Plane for Infectious Disease Consult vs No Consult

This supplemental material has been provided by the authors to give readers additional information about their work.
### eTable. Characteristics of Studies Used to Obtain Base-Case Effectiveness Estimates

| Study Author | Study Design, Duration of Study, Country | Mean or Median age (in years) | Number of participants with male gender | Number of participants with MRSA | ID consult Total Population | No ID consult total population | Timing of ID consultation |
|--------------|----------------------------------------|------------------------------|----------------------------------------|---------------------------------|-----------------------------|-----------------------------|--------------------------|
| Bai 2015     | Retrospective, cohort, multicenter, 36 months, Canada | ID consult: 63, No ID consult: 68 | ID consult: 332, No ID consult: 213 | 145 | 506 | 341 | Within 7 days of blood culture collection or ID specialist as the responsible physician |
| Forsblom 2013 | Retrospective, cohort, single-center, 60 months, Finland | ID consult: 53.2, No ID consult: 55.2 | ID consult: 160, No ID consult: 21 | 0 | 244 | 26 | Within 1 week after the first positive blood culture |
| Honda 2010   | Retrospective, case-control, single-center, 36 months, USA | ID consult: 56, No ID consult: 56 | ID consult: 56, No ID consult: 133 | 185 | 111 | 230 | 78% were obtained within 5 days after the first positive blood culture |
| Jenkins 2008 | Prospective, case-control, single center, 2x12 months, USA | ID consult: 47, No ID consult: 50 | ID consult: 87, No ID consult: 61 | 78 | 100 | 134 | Typically within 48 h of collection of the initial positive culture specimen |
| Jogenfors 2013 | Retrospective, cohort, single-center, Sweden | ID consult: -, No ID consult: - | ID consult: 62, No ID consult: 35 | 0 | 100 | 58 | From first positive blood culture |
| Lopez-Cortes 2013 | Prospective, quasi-experimental, multicenter, 2x6 months, Spain | ID consult: 67, No ID consult: 66 | ID consult: 140, No ID consult: 198 | 102 | 162 | 287 | From first positive blood culture |
| Pragmann 2012 | Retrospective, cohort, single-center, 77 months, USA | ID consult: 66, No ID consult: 68 | ID consult: 178, No ID consult: 52 | 136 | 149 | 36 | Not specified |
| Rieg 2009    | Retrospective, cohort, single-center, 72 months, Germany | ID consult: 61%>60, No ID consult: 61%>60 | ID consult: -, No ID consult: - | 67 | 300 | 131 | Primary physician was alerted of positive blood cultures within 36h and could call ID consult at their discretion |
| Saunders on 2015 | Observational, cohort, single center, 78 months, UK | ID consult: 64.8, No ID consult: 65.8 | ID consult: 103, No ID consult: 184 | 127 | 36 | 30 | Initial consult at the diagnosis of SAB |
eFigure 1. Incremental Cost-effectiveness Plane for Infectious Disease Consult vs No Consult

The y-axis represents incremental cost while the x-axis represents incremental effectiveness.